Michael A. James, PhD

Publications

• Single-nucleotide polymorphism rs13426236 contributes to an increased prostate cancer risk via regulating MLPH splicing variant 4.

  (Xiao F, Zhang P, Wang Y, Tian Y, James M, Huang CC, Wang L, Wang L.) Mol Carcinog. 2020 Jan;59(1):45-55 PMID: 31659808 SCOPUS ID: 2-s2.0-85074694919 10/30/2019

• CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.

  (Clarke WR, Amundadottir L, James MA.) Int J Cancer. 2019 03 15;144(6):1367-1378 PMID: 30468251 SCOPUS ID: 2-s2.0-85059544138 11/24/2018

• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

  (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335 PMID: 29587663 PMCID: PMC5870823 SCOPUS ID: 2-s2.0-85044523365 03/29/2018

• Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.

  (Bodle CR, Mackie DI, Hayes MP, Schamp JH, Miller MR, Henry MD, Doorn JA, Houtman JCD, James MA, Roman DL.) J Nat Prod. 2017 07 28;80(7):1992-2000 PMID: 28621943 PMCID: PMC5567870 SCOPUS ID: 2-s2.0-85026545039 06/18/2017

• Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.

  (Puskás LG, Mán I, Szebeni G, Tiszlavicz L, Tsai S, James MA.) Mol Cancer Ther. 2016 05;15(5):985-97 PMID: 26939707 PMCID: PMC4873426 SCOPUS ID: 2-s2.0-84969522621 03/05/2016

• Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.

  (Lee Y, Wang Y, James M, Jeong JH, You M.) Mol Carcinog. 2016 May;55(5):991-1001 PMID: 26052929 PMCID: PMC6003619 SCOPUS ID: 2-s2.0-84930532549 06/09/2015

• Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus.

  (Lieberman R, Xiong D, James M, Han Y, Amos CI, Wang L, You M.) Mol Carcinog. 2016 May;55(5):953-63 PMID: 26013599 PMCID: PMC4662629 SCOPUS ID: 2-s2.0-84930260740 05/28/2015

• A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.

  (James MA, Seibel WL, Kupert E, Hu XX, Potharla VY, Anderson MW.) Anticancer Drugs. 2015 Jun;26(5):518-30 PMID: 25646742 SCOPUS ID: 2-s2.0-84939967936 02/04/2015

• CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.

  (James MA, Vikis HG, Tate E, Rymaszewski AL, You M.) Cancer Res. 2014 Feb 15;74(4):1116-27 PMID: 24366883 PMCID: PMC6005686 SCOPUS ID: 2-s2.0-84894226710 12/25/2013

• Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

  (James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M.) PLoS One. 2012;7(6):e36116 PMID: 22675468 PMCID: PMC3366984 SCOPUS ID: 2-s2.0-84861899749 06/08/2012

• Stromal inflammation in pancreatic cancer: Mechanisms and translational applications

  (Boyle KA, James MA, Tsai S, Evans DB, Dwinell MB.) Pancreatic Cancer. 11 April 2018:481-508 SCOPUS ID: 2-s2.0-85054043119 04/11/2018

• Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications

  (Boyle K, James MA, Tsai S, Evans DB, Dwinell MB..) Pancreatic Cancer. 2nd Ed. Springer-Verlag New York. DOI: 10.1007/978-1-4939-6631-8_55-1 01/01/2017